The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
REFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design.
 
Michael Seckl
Consulting or Advisory Role - Bristol-Myers Squibb
Expert Testimony - Teva
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Ehsan Ghorani
Patents, Royalties, Other Intellectual Property - patent on molecules associated with T cell dysfunction
 
Matteo Quartagno
No Relationships to Disclose
 
Fiona Helen Blackhall
Honoraria - Amgen; AstraZeneca; AstraZeneca; Bayer; Medivation; Pfizer; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Amgen; AstraZeneca; AstraZeneca; Blueprint Medicines; cell Medica; Janssen; Medivation; Pfizer
Speakers' Bureau - AstraZeneca; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Blueprint Medicines; Boehringer Ingelheim (Inst); Bristol Myers Squibb Foundation (Inst); Celgene; Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Duncan C. Gilbert
No Relationships to Disclose
 
Mary E.R. O'Brien
Employment - Oxford Biomedica (I)
Honoraria - Abbvie; Bristol-Myers Squibb; Merck; Merck; Merck Serono
Consulting or Advisory Role - Eisai Europe; ITeos Therapeutics; Merck; Merck; PharmaMar; PharmaMar; Pierre Fabre; Puma Biotechnology
Patents, Royalties, Other Intellectual Property - Book: Fast fact NSCLC edition 1 and 2, published by Karger (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Christian H.H Ottensmeier
Stock and Other Ownership Interests - NEUVOGEN
Honoraria - Delcath Systems; Transgene
Consulting or Advisory Role - Bristol-Myers Squibb; Delcath Systems; Merck Sharp & Dohme; NEUVOGEN
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme
Research Funding - BioNTech (Inst); Bristol-Myers Squibb (Inst); Delcath Systems (Inst); Merck Sharp & Dohme (Inst); PsiOxus Therapeutics (Inst); Scancell (Inst); Touchlight Genetics (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Delcath Systems
Other Relationship - Transgene
 
Elena Pizzo
No Relationships to Disclose
 
James F. Spicer
Stock and Other Ownership Interests - IGEM Therapeutics
Consulting or Advisory Role - Apobec Discovery (Inst); Avacta Life Sciences (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Roche (Inst)
Research Funding - Achilles Therapeutics (Inst); BerGenBio (Inst); BluPrint Oncology (Inst); BluPrint Oncology (Inst); Bristol-Myers Squibb (Inst); Genmab (Inst); IO Biotech (Inst); Roche (Inst); RS Oncology (Inst); Starpharma (Inst); Trizell (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Janssen
 
Alex Williams
No Relationships to Disclose
 
Philip David Badman
No Relationships to Disclose
 
Mahesh K. B. Parmar
No Relationships to Disclose